Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

Objectives The maximum tolerated dose (MTD) and overall safety of sunitinib plus pemetrexed and carboplatin was determined in patients with advanced solid malignancies. Methods In this phase I dose-escalation study, patients received oral sunitinib on a continuous daily dosing (CDD) schedule (37.5 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Blais, Normand, Camidge, D. Ross, Jonker, Derek J., Soulières, Denis, Laurie, Scott A., Diab, Sami G., Ruiz-Garcia, Ana, Thall, Aron, Zhang, Ke, Chao, Richard C., Chow, Laura Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825543/
https://www.ncbi.nlm.nih.gov/pubmed/23963796
http://dx.doi.org/10.1007/s10637-013-0010-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825543/
https://www.ncbi.nlm.nih.gov/pubmed/23963796
http://dx.doi.org/10.1007/s10637-013-0010-4

Ejemplares similares